Iopimax

Apraclonidine, the active ingredient in Iopimax, is a alpha-2 adrenergic agonist presented as a topical ophthalmic solution for ocular use. It is used to lower intraocular pressure in patients with ocular hypertension or open‑angle glaucoma. GNH USA supplies Iopimax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Apraclonidine is indicated for conditions affecting aqueous humor dynamics and intraocular pressure. - Ocular hypertension: reduces intraocular pressure to prevent progression to glaucoma. - Open‑angle glaucoma: lowers pressure to protect optic nerve function. - Reduction of intraocular pressure: assists in overall management of elevated eye pressure across related disorders.

Adverse reactions may occur with topical ocular use of apraclonidine.

Common Side Effects: - Burning or stinging sensation upon instillation. - Redness of the conjunctiva. - Transient blurred vision. - Mild ocular discomfort. - Dry eye sensation. - Mild headache.

Serious or Rare Side Effects: - Allergic contact dermatitis of the eyelid. - Severe ocular inflammation or uveitis. - Persistent hypotony (abnormally low eye pressure). - Systemic hypotension or bradycardia in susceptible patients. - Vision loss due to optic nerve compromise. - Anaphylactic reaction (extremely rare).

Before using apraclonidine eye drops, consider the following precautions. - Pregnancy: safety not established; avoid unless benefits outweigh risks. - Breastfeeding: unknown excretion; discuss with healthcare provider. - Pre‑existing cardiovascular disease: monitor for systemic hypotension. - Concomitant use of other ocular hypotensive agents: assess additive pressure‑lowering effect. - History of allergic reactions to ophthalmic solutions: evaluate risk of dermatitis. - Store below 25°C: keep in original container, protect from light and moisture.

Apraclonidine may interact with other medications affecting ocular or systemic adrenergic pathways.

Major Interactions (Avoid): - Systemic alpha‑2 agonists (e.g., clonidine) – may cause additive hypotensive effects. - Non‑selective beta‑blockers used ophthalmically – risk of excessive intraocular pressure reduction.

Moderate Interactions (Monitor Closely):\n- Topical prostaglandin analogues – monitor for unexpected pressure changes. - Anticholinergic eye drops – observe for altered pupil response. - Systemic antihypertensives – watch for synergistic blood pressure lowering.